drugset / Trial / NCT05289323

Effect of Intrathecal Neostigmine on Post-dural Puncture Headache.

NCT05289323

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Intravenous neostigmine was recently reported as an effective treatment for PDPH for parturients after intrathecal (IT) block which is postulated to be through its central effects on CSF secretion and cerebral vascular tone modulation. Intrathecal neostigmine has been investigated widely and found to be an effective adjuvant to bupivacaine for postoperative analgesia. The objective of the current study is to investigate the possible prophylactic role of intrathecal neostigmine as an adjuvant to bupivacaine in reducing the incidence and severity of post-dural puncture headache in parturients scheduled for an elective cesarean section.

Timeline

Start
2022-04-25
Primary completion
2023-07-25
Completion
2023-07-25

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Neostigmine Methylsulfate Small molecule 20 ug Intrathecal